Remove Chemotherapy Remove Labelling Remove Mayo Clinic
article thumbnail

ASH roundup: late breakers take the stage

pharmaphorum

At ASH, the E1910 clinical trial generated results could unlock a new patient population for Blincyto, after it was shown to improve overall survival in patients with no measurable residual disease (MRD) after induction chemotherapy for B-ALL. At the moment, Blincyto is approved to treat patients with MRD after induction treatment.

article thumbnail

CoQ10 side effects and how to avoid them

The Checkup by Singlecare

People with cancer : There is little information about the interactions between CoQ10 and cancer chemotherapy, so healthcare professionals may advise against its use during cancer treatment. Side effects are minimal and experienced in less than 1% of people taking the supplement, according to the drug label.

FDA 52